PROF Profound Medical Corp.

Nasdaq profoundmedical.com


$ 6.20 $ -0.12 (-1.85 %)    

Thursday, 13-Nov-2025 16:10:53 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 6.35
$ 6.45
$ 5.10 x 15
$ 6.40 x 1
-- - --
$ 3.76 - $ 8.75
84,962
na
191.73M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-07-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 profound-medical-q3-eps-026-beats-036-estimate-sales-5289m-beat-4995m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0....

Core News & Articles

Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage m...

Core News & Articles

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device ...

Core News & Articles

Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage m...

Core News & Articles

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device ...

 profound-medical-q2-eps-052-misses-035-estimate-sales-2211m-miss-3533m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(...

Core News & Articles

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device ...

 profound-medical-q1-eps-036-misses-028-estimate-sales-262m-miss-350m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(...

Core News & Articles

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer –– TULSA had no blood l...

 lake-street-maintains-buy-on-profound-medical-lowers-price-target-to-11

Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target from $17...

 profound-medical-q4-eps-020-beats-033-estimate-sales-418m-miss-427m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION